WO2007127145A3 - Methods and compositions for treatment of cardiac arrhythmia in non-human animals - Google Patents

Methods and compositions for treatment of cardiac arrhythmia in non-human animals Download PDF

Info

Publication number
WO2007127145A3
WO2007127145A3 PCT/US2007/009715 US2007009715W WO2007127145A3 WO 2007127145 A3 WO2007127145 A3 WO 2007127145A3 US 2007009715 W US2007009715 W US 2007009715W WO 2007127145 A3 WO2007127145 A3 WO 2007127145A3
Authority
WO
WIPO (PCT)
Prior art keywords
calstabin2
formula
fkbp
human animals
compositions
Prior art date
Application number
PCT/US2007/009715
Other languages
French (fr)
Other versions
WO2007127145A2 (en
Inventor
Andrew Robert Marks
Mark Oyama
Original Assignee
Univ Columbia
Andrew Robert Marks
Mark Oyama
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/032405 external-priority patent/WO2007024717A2/en
Application filed by Univ Columbia, Andrew Robert Marks, Mark Oyama filed Critical Univ Columbia
Publication of WO2007127145A2 publication Critical patent/WO2007127145A2/en
Publication of WO2007127145A3 publication Critical patent/WO2007127145A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/111—Aromatic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/137—Heterocyclic compounds containing two hetero atoms, of which at least one is nitrogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Animal Husbandry (AREA)
  • Food Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides methods for detecting an arrhythmogenic condition in a subject non-human animal, such as a canine of the breed Boxer, comprising measuring a level of calstabin2 (FKBP 12.6) in cardiac tissue of the subject non-human animal, wherein the method measures and compares calstabin2 mRNA and/or levels of calstabin2 (FKBP 12.6) protein in the RyR2-calstabin2 protein complex in cardiac tissue, wherein a reduced level of calstabin2 (FKBP 12.6) is indicative of an arrhythmogenic condition. The present invention also provides methods for treating or preventing an arrhythmogenic condition in non-human animals, comprising administering an agent known to affect the interaction between calstabin2 and RyR2, wherein the agent is selected from the group of compounds of Formula (I) and Formula (II). The invention further provides animal feed compositions comprising compounds of Formula (I) and Formula (II).
PCT/US2007/009715 2006-04-25 2007-04-23 Methods and compositions for treatment of cardiac arrhythmia in non-human animals WO2007127145A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US79520506P 2006-04-25 2006-04-25
US60/795,205 2006-04-25
PCT/US2006/032405 WO2007024717A2 (en) 2005-08-25 2006-08-17 Agents for preventing and treating disorders involving modulation of the ryr receptors
USPCT/US2006/032405 2006-08-17

Publications (2)

Publication Number Publication Date
WO2007127145A2 WO2007127145A2 (en) 2007-11-08
WO2007127145A3 true WO2007127145A3 (en) 2008-10-23

Family

ID=38656113

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/009715 WO2007127145A2 (en) 2006-04-25 2007-04-23 Methods and compositions for treatment of cardiac arrhythmia in non-human animals

Country Status (1)

Country Link
WO (1) WO2007127145A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
EP2708535A1 (en) 2012-05-11 2014-03-19 Les Laboratoires Servier Agents for treating disorders involving modulation of ryanodine receptors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215540A1 (en) * 2004-01-22 2005-09-29 Marks Andrew R Novel anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215540A1 (en) * 2004-01-22 2005-09-29 Marks Andrew R Novel anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
TIDHOLM ET AL.: "Canine Idiopathic Dilated Cardiomyopathy", March 2002 (2002-03-01) *
XANDER H.T. WEHRENS ET AL: "Sudden Unexplained Death Caused by Cardiac Ryanodine Receptor (RyR2) Mutations", MAYOCLINIC PROC., vol. 79, no. 11, November 2004 (2004-11-01), pages 1367 - 1371 *
YANO ET AL.: "FKBP12.6-Mediated Stabilization ofCalcium-release", CIRCULATION JANUARY, vol. 107, 2003, pages 477 - 484, XP002990501 *

Also Published As

Publication number Publication date
WO2007127145A2 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
Wright-Williams et al. Effects of vasectomy surgery and meloxicam treatment on faecal corticosterone levels and behaviour in two strains of laboratory mouse
de Boer et al. 5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis
Koch et al. Role of nucleus accumbens dopamine D 1 and D 2 receptors in instrumental and Pavlovian paradigms of conditioned reward
Zelena et al. Role of hypothalamic inputs in maintaining pituitary-adrenal responsiveness in repeated restraint
De Almeida et al. 8-OH-DPAT in the median raphe, dorsal periaqueductal gray and corticomedial amygdala nucleus decreases, but in the medial septal area it can increase maternal aggressive behavior in rats
WO2005110982A3 (en) Substituted 1-benzyl-4-substituted piperazine analogues
WO2004071448A3 (en) Substituted azole derivatives as inhibitors of protein tyrosine phosphatases
WO2004071447A3 (en) Substituted azole derivatives as therapeutic agents
WO2006009789A3 (en) Aryl-substituted piperazine derivatives
Minghetti et al. Copper transporter 1, metallothionein and glutathione reductase genes are differentially expressed in tissues of sea bream (Sparus aurata) after exposure to dietary or waterborne copper
Roberts Scent marking
WO2006017443A3 (en) Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
WO2008117125A3 (en) Compositions capable of facilitating penetration across a biological barrier
TW200634006A (en) Tetrahydroquinoline analogues as muscarinic agonists
WO2007089857A3 (en) Substituted imidazole derivatives and their use as ptpase inhibitors
BRPI0515261A (en) compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, use of the chemical compound or any of its isomers or any mixture of isomers thereof, or a pharmaceutically acceptable salt thereof, and a method for treating, preventing or relief from a disease or disorder or condition of a living animal body
EP2476761A3 (en) Polynucleotide marker genes and their expression, for diagnosis of endotoxemia
WO2005084401A3 (en) Aryl substituted purine analogues
MX2007003094A (en) 4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists.
Yamashita et al. Gustatory responses to feeding‐and non‐feeding‐stimulant chemicals, with an emphasis on amino acids, in rainbow trout
Volkoff The effects of amphetamine injections on feeding behavior and the brain expression of orexin, CART, tyrosine hydroxylase (TH) and thyrotropin releasing hormone (TRH) in goldfish (Carassius auratus)
DE602005022693D1 (en) Cancer diagnosis and treatment using an anti-ROBO1 antibody
Shi et al. The bioaccumulation of fluoride ion (F−) in Siberian sturgeon (Acipenser baerii) under laboratory conditions
WO2001092567A3 (en) Novel target genes for diseases of the heart
Dogan et al. Effects of lead on ATPases in tissues of freshwater fish (Oreochromis niloticus) in differing calcium levels

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07755832

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07755832

Country of ref document: EP

Kind code of ref document: A2